Artwork

Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Can cell therapy tackle hearing loss?

31:00
 
Share
 

Manage episode 421262836 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Hearing loss is a huge – and growing – global challenge.

Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge.

The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. The company is looking to start first-in-human trials in 2025.

Today, on the podcast we have a conversation with Rinri CEO Simon Chandler about the different kinds of hearing loss, what’s being done to tackle them, and Rinri’s novel approach to treatments.

01:08-03:19: About Rinri Therapeutics
03:19-05:16: About hearing loss
05:16-07:31: Mental health and hearing loss
07:31-10:22: The different kinds of hearing loss
10:22-11:37: The importance of early intervention
11:37-13:46: What is Rinri doing to tackle hearing loss?
13:46-15:58: The difficulty of accessing the cochlea
15:58-19:12: Is your treatment a cure for hearing loss?
19:12-20:45: Would repeat treatment be necessary?
20:45-23:30: Are other companies working on hearing loss?
23:30-25:27: The cost of treating hearing loss
25:27-27:13: The economic costs of hearing loss
27:13-28:33: Rinri treatment timelines
28:33-30:15: The rest of Rinri’s pipeline
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Chapters

1. Can cell therapy tackle hearing loss? (00:00:00)

2. About Rinri Therapeutics
 (00:01:08)

3. About hearing loss (00:03:19)

4. Mental health and hearing loss
 (00:05:16)

5. The different kinds of hearing loss (00:07:31)

6. The importance of early intervention
 (00:10:22)

7. What is Rinri doing to tackle hearing loss?
 (00:11:37)

8. The difficulty of accessing the cochlea
 (00:13:46)

9. Is your treatment a cure for hearing loss?
 (00:15:58)

10. Would repeat treatment be necessary?
 (00:19:12)

11. Are other companies working on hearing loss?
 (00:20:45)

12. The cost of treating hearing loss
 (00:23:30)

13. The economic costs of hearing loss
 (00:25:27)

14. Rinri treatment timelines
 (00:27:13)

15. The rest of Rinri’s pipeline
 (00:28:33)

102 episodes

Artwork
iconShare
 
Manage episode 421262836 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Hearing loss is a huge – and growing – global challenge.

Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge.

The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. The company is looking to start first-in-human trials in 2025.

Today, on the podcast we have a conversation with Rinri CEO Simon Chandler about the different kinds of hearing loss, what’s being done to tackle them, and Rinri’s novel approach to treatments.

01:08-03:19: About Rinri Therapeutics
03:19-05:16: About hearing loss
05:16-07:31: Mental health and hearing loss
07:31-10:22: The different kinds of hearing loss
10:22-11:37: The importance of early intervention
11:37-13:46: What is Rinri doing to tackle hearing loss?
13:46-15:58: The difficulty of accessing the cochlea
15:58-19:12: Is your treatment a cure for hearing loss?
19:12-20:45: Would repeat treatment be necessary?
20:45-23:30: Are other companies working on hearing loss?
23:30-25:27: The cost of treating hearing loss
25:27-27:13: The economic costs of hearing loss
27:13-28:33: Rinri treatment timelines
28:33-30:15: The rest of Rinri’s pipeline
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Chapters

1. Can cell therapy tackle hearing loss? (00:00:00)

2. About Rinri Therapeutics
 (00:01:08)

3. About hearing loss (00:03:19)

4. Mental health and hearing loss
 (00:05:16)

5. The different kinds of hearing loss (00:07:31)

6. The importance of early intervention
 (00:10:22)

7. What is Rinri doing to tackle hearing loss?
 (00:11:37)

8. The difficulty of accessing the cochlea
 (00:13:46)

9. Is your treatment a cure for hearing loss?
 (00:15:58)

10. Would repeat treatment be necessary?
 (00:19:12)

11. Are other companies working on hearing loss?
 (00:20:45)

12. The cost of treating hearing loss
 (00:23:30)

13. The economic costs of hearing loss
 (00:25:27)

14. Rinri treatment timelines
 (00:27:13)

15. The rest of Rinri’s pipeline
 (00:28:33)

102 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide